ArticleIn vivo (Athens, Greece)

Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.

Hiroyoshi Koide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.